ArticleOpen veterinary journal2026
Acetyl-L-carnitine protective role in gemcitabine-induced neurotoxicity in an experimental rat model.
Article in Open veterinary journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The acetyl ester of L-carnitine (ALC) is essential for cellular energy homeostasis and intermediate metabolism. It demonstrates several well-established biological characteristics, such as antioxidant activity, intracellular membrane stability, mitochondrial function improvement, and neuroprotective and neurotrophic effects. Given that oxidative stress, mitochondrial malfunction, and neuronal membrane damage have been linked to gemcitabine-induced neurotoxicity, ALC may have a preventive role against these negative consequences. Its capacity to boost mitochondrial metabolism and act as an antioxidant points to a potential mechanism for reducing damage to the central nervous system (CNS) caused by gemcitabine. Thus, using an experimental model of gemcitabine-induced neurotoxicity, we explored the possible neuroprotective benefits of ALC. Aim: This study aimed to examine the neuroprotective effects of two distinct dosages of ALC on cognitive impairment in male rats caused by gemcitabine injection. Cognitive function was assessed using well-known behavioral tests, such as the Morris water maze or novel object identification, to offer objective measures of learning and memory. This study aimed to elucidate the possible function of ALC in reducing gemcitabine-related CNS toxicity by evaluating behavioral performance in addition to biochemical indicators of oxidative stress and neuronal damage. It is anticipated that the results of this study will shed light on the dose-dependent effectiveness of ALC in maintaining cognitive function after chemotherapy. Methods: The experiment was conducted using 24 adult male rats, which were randomly assigned to four equal groups ( Results: Rats receiving ALC in addition to gemcitabine demonstrated a significant reduction in gemcitabine-induced adverse effects ( Conclusion: The fourth experimental group (G4) had considerably lower levels of β-amyloid and acetylcholinesterase activity than the second (G2) and third (G3) groups. Furthermore, brain sections from the G4 group showed significantly fewer β-amyloid plaques than those from the G2 and G3 groups, according to Congo red staining histological analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.